###### Strengths and limitations of this study

-   Given the market size of statins and a number of 'me-too' drugs and generic statins, statin utilisation, including switching drugs, in health systems has been the subject of considerable interest.

-   The National Health Insurance Service-National Sample Cohort, a population-based cohort, provides public health researchers useful information regarding utilisation of health services.

-   This 13-year longitudinal study of a sample cohort presented that the incidence of new statin user increase from 838.1/100 000 persons in 2003 to 1626.9/100 000 persons in 2015.

-   Patterns of prescription and market dynamics of statins found in this study is quite different from other studies in different regions.

-   Interestingly, discounted price of originals after the introduction of generics immediately expand markets or substitute the market particularly in primary healthcare institutions in Korea.

Introduction {#s1}
============

Cardiovascular diseases (CVDs) account for 31% of all global deaths, taking the lives of 17.7 million people annually.[@R1] Similarly, CVDs are among the leading causes of death in South Korea (hereafter Korea).[@R2] Hypercholesterolaemia is a well-established but modifiable risk factor for CVDs.[@R4] Lifestyle changes and several types of medications have been recommended to control blood lipid levels. Among the medications, statins are a major drug class that functions in reducing low-density lipoprotein cholesterol (LDL-C).[@R9] Specifically, statins are recommended by several clinical guidelines, including the American College of Cardiology/American Heart Association Guideline,[@R10] the European Society of Cardiology (ESC)[@R9] and the UK's National Institute for Health and Care Excellence Guideline,[@R11] as the drug of choice for reduction of blood lipids to prevent CVDs.

In recent decades, statins have been the most commonly prescribed drugs in the world, and their global market sales reached approximately \$28.5 billion in 2014.[@R16] Studies from several countries reported substantial increases in prescription rates of statins, including increased daily doses of statins.[@R17] Likewise, drug expenditure for statins has increased from 496 billion won in 2010 to 786 billion won in 2016 in Korea.[@R2] It should also be noted that there are many 'me-too' drugs, including generics or follow on drugs, under the statin category.[@R12] For example, atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin, as well as a number of generics, are now available for patients with hypercholesterolaemia in the Korean market.

Given the market size of statins and a number of 'me-too' drugs and generic statins, statin utilisation, including switching drugs, in health systems has been the subject of considerable interest in the perspective of clinical pharmacy and public health.[@R22] For instance, several European countries have restricted the prescribing of patented statins when generic statins became available at a much lower cost.[@R29] However, notably few studies have dealt empirically with the issue or included real-world data with statin users, especially in Korea. Meanwhile, it was reported that drug switching among statin users is low in Korea.[@R2] Therefore, we selected new statin users to understand statin utilisation and market dynamics of statins in Korea. Given the limited drug switching among statin users, analysing statin utilisation of new users could be used as an important resource to evaluate the use of statins and to assess market dynamics of statins in Korea.

This study analysed the utilisation of statins for new statin users and assessed the market dynamics of statins. Specifically, this study examined characteristics of new statin users and the prescribing of statin drugs over the last 13 years, investigated the association between medical history of patients and intensity of statins and analysed market dynamics of statins, including market penetration and switching among new statin users.

Methods {#s2}
=======

Data source {#s2a}
-----------

This study used the National Health Insurance Service-National Sample Cohort (NHIS-NSC), a population-based cohort established by the National Health Insurance Service.[@R31] The dataset is composed of approximately 1 million individuals (approximately 2% of the population) selected randomly from South Koreans. The NHIS built a target population of 46 605 433 individuals in 2002, and then 1 025 340 participants was randomly selected from the target population. Specifically, systematic stratified random sampling with proportional allocation within each stratum was conducted to construct the cohort.[@R31]

The cohort dataset consists of four databases on participants' insurance eligibility, medical treatments, healthcare institutions and general health examinations for the period from 1 January 2002 to 31 December 2015.[@R31] The dataset provides information on demographic and socioeconomic characteristics, such as age, gender and level of income. Income level was calculated based on the insurance premium that participant pays. Also, patients' disease diagnosis was coded based on the International Classification of Diseases-10th Revision (ICD-10), and the corresponding medical expenditures such as medical and prescription information are available. The prescription information covers the date and duration of the prescription, the prescribed drugs' international non-proprietary names, dosage, the route of administration, prescribers' specialty and the types of the healthcare institution.

Study design {#s2b}
------------

This study is interested in new statin users. New statin users were defined as those who had not been prescribed any statin in the year prior to the date of the first statin prescription observed in the cohort dataset.[@R32] Therefore, new statin users in each year from 2003 to 2015 were included in the study population of each year. Specifically, the first prescription for outpatients that included any statin was set as an index date and analysed in the study.

The studied drugs include the statins atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin. The information of individual drugs marketed in Korea are stated in online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}. In this study, we defined monotherapy as only one statin prescription, while we defined combination therapy as prescription for a statin plus other lipid-lowering drugs, including fibrates or ezetimibe. In addition, we searched the market of statins in Korea, including the entry of new drugs and follow on drugs and their pricing information on the website of the Ministry of Food and Drug Safety (available at <http://drug.mfds.go.kr/html/search_total_download_itemPermit.jsp>)and the Health Insurance Review and Assessment Service (available at <https://biz.hira.or.kr/popup.ndo?formname=qya_bizcom%3A%3AInfoBank.xfdl&framename=InfoBank>), respectively. In Korea, copayment for medicines that prescribed for outpatients are 30% of total expenditure, including pharmacy preparation charge, thus financial burden is less likely to influence the statin adherence, unlike previous study.[@R33]
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Statins were grouped into three levels of intensity[@R10]: high-intensity statins, moderate-intensity statins and low-intensity statins. Daily doses can be calculated from the prescription data. High-intensity statins include atorvastatin 40--80 mg/day, rosuvastatin 20--40 mg/day and simvastatin 80 mg/day. Low-intensity statins include simvastatin 10 mg/day, pravastatin 10--20 mg/day, lovastatin 20 mg/day, pitavastatin 1 mg/day and fluvastatin 20--40 mg/day. Lastly, moderate-intensity statins include atorvastatin 10--20 mg/day, rosuvastatin 5--10 mg/day, simvastatin 20--40 mg/day, pravastatin 40--80 mg/day, lovastatin 40 mg/day, pitavastatin 2--4 mg/day and fluvastatin 80 mg/day.

All new statin users were classified based on their disease history, including hypertension (I10--I15), diabetes (E10--E14), diseases of arteries, arterioles and capillaries (I70--I79), ischaemic heart disease (I20--I25), cerebrovascular diseases (I60--I69), chronic obstructive pulmonary disease (J44), heart failure (I50), chronic kidney diseases (N17--N19) and atrial fibrillation (I48). Disease history was identified by the ICD-10 codes. Among these diseases, diabetes, diseases of arteries, arterioles and capillaries, cerebrovascular diseases and heart failure are related to the use of statins for CVD prevention.[@R14] Individuals were identified as having a disease history of the specific disease if they had a primary diagnosis that corresponded to each diagnosis within 3 years prior to the first prescription date.[@R37]

Lastly, to investigate the association between the providers' characteristics and the intensity of the statin prescribed, we sorted medical institutions by primary, secondary and tertiary institutions. Primary care institutions include clinic-level medical institutions that provide medical services to outpatients. Secondary care institutions include hospital-level medical institutions that provide health services primarily to inpatients. Tertiary care institutions include superior general hospitals, designated by the Minister of Health and Welfare, that provide medical service requiring high level of expertise for treating serious disease.

Data analysis {#s2c}
-------------

This study used descriptive statistics to examine characteristics of new statin users and prescribed statin drugs, employed the χ[@R2] test to investigate the associations between certain disease history and prescription of moderate-intensity or high-intensity statins and applied interrupted time series analysis to understand the market dynamics of statins. In time series analysis, we estimated the effect of the introduction of generics on the market, specifically for newly prescribed statin users.[@R39] We presented the result of simple linear regression before and after the introduction of generics.[@R40]

$$Y_{t} = \beta_{0} + \beta_{1}T + \beta_{2}X_{t} + \beta_{3}TX_{t}$$

Y~t~: the number of new users that prescribed the certain statin at time t.

T: the time elapsed since the start of the study.

X~t~: a dummy variable indicating the preintervention period or the postintervention period.

It should be noted that we defined the intervention year as the year when the price of originals were discounted due to the entry of follow on drugs. Generally speaking, the price of originals was discounted as soon as the entry of the follow-on drugs, in case of atorvastatin that occurred in 2008. However, the price reduction of original rosuvastatin was deferred until 2014 for the reason of valid patent that original rosuvastatin has until 2014, even though the follow-on drugs were available in 2008. Therefore, we used the year of 2008 and 2014 as the intervention year of the model for atorvastatin and rosuvastatin, respectively. Data management and analysis were performed using the R statistical software (V.3.4.1). P values under 0.05 were considered to be of significance.

Ethical statement {#s2d}
-----------------

This study used a deidentified secondary dataset. Therefore, it was exempted from review by the Institutional Review Board (IRB) of Ewha Womans University (IRB No. 158--10).

Patient and public involvement {#s2e}
------------------------------

No patients were involved in developing the research question, outcome measure and design of the study. We are unable to disseminate the results of the research directly to study participants.

Results {#s3}
=======

Characteristics of new statin users over time {#s3a}
---------------------------------------------

[Table 1](#T1){ref-type="table"} presents characteristics of new statin users over time. Incidence of new statin user increase from 838.1/100 000 persons in 2003 to 1626.9/100 000 persons in 2015. There have been more female new users than male new users, while the portion of female new statin users steadily declined from 56.5% in 2003 to 50.4% in 2015. During this period, the average age of new statin users with SD remained steady (54.31--56.52 years old with 11.82--12.89 SD). We also sorted new statin users by their income quintile. The portion of the first quintile (the lowest income) increased from 13% in 2003 to 16% in 2015, while the portion of the fifth quintile (the highest income) decreased from 33% in 2003 to 30% in 2015. In 2003, hypertension accounted for the highest portion of comorbidities (55%), followed by diabetes (37%), ischaemic heart disease (21%), diseases of arteries, arterioles and capillaries (14%) and cerebrovascular diseases (12%). These trends remained steady in 2015.

###### 

Characteristics of new statin users over time

  ----------------------------------------------------------------------------------------------------------------------------------------------------
                                    2003    2004    2005     2006     2007     2008     2009     2010     2011     2012     2013     2014     2015
  --------------------------------- ------- ------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- --------
  Incidence\                        838.1   893.2   1118.2   1256.4   1277.4   1341.7   1532.3   1497.8   1472.4   1508.4   1463.5   1640.3   1626.9
  (100 000 person)                                                                                                                            

  Sex                                                                                                                                         

   Female (%)                       56.5    55.0    56.8     55.8     54.8     54.3     55.2     54.6     53.2     53.1     52.0     50.7     50.4

  Age                                                                                                                                         

   Mean                             54.40   54.31   55.15    55.61    55.62    55.48    55.61    55.71    55.58    55.65    55.57    56.52    55.90

   SD                               11.82   12.00   12.15    12.47    12.68    12.52    12.51    12.39    12.46    12.71    12.89    12.79    12.75

  Income level (the quintile) (%)                                                                                                             

   The first                        13      14      15       15       15       14       15       15       15       15       16       16       16

   The second                       13      13      12       14       13       14       14       15       15       15       14       15       15

   The third                        17      17      18       16       18       18       18       17       18       17       17       17       17

   The fourth                       24      23      22       23       23       23       23       23       22       22       23       22       22

   The fifth                        33      32      33       32       32       31       30       31       30       30       30       30       30

  Comorbidities (%)                                                                                                                           

   Hypertension                     N/A     55      59       58       58       56       54       53       53       52       52       48       

   Diabetes                         37      39      40       39       37       36       36       37       38       41       39                

   DoA                              14      17      20       24       25       25       23       22       21       22       20                

   IHD                              21      22      22       21       19       19       19       18       17       18       16                

   CeVD                             12      13      15       15       15       15       14       15       15       14       14                

   COPD                             5       6       6        6        5        5        5        5        5        5        4                 

   Heart failure                    5       4       4        4        3        4        4        4        4        4        4                 

   CKD                              2       2       2        2        2        2        2        2        3        3        3                 

   Afib                             2       2       2        3        2        2        2        2        2        3        2                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------

Afib, atrial fibrillation; CeVD, cerebrovascular diseases; CKD, chronic kidney diseases; COPD, chronic obstructive pulmonary disease; DoA, diseases of arteries, arterioles and capillaries; IHD, ischaemic heart disease.

Characteristics of prescribed statin drugs among new statin users {#s3b}
-----------------------------------------------------------------

[Table 2](#T2){ref-type="table"} shows characteristics of prescribed statin drugs among new statin users. The majority of patients were prescribed with a single statin (monotherapy) when they started hypercholesterolaemia treatment, while few new users were prescribed combination therapy during the study period.

###### 

Characteristics of prescribed statin drugs among new statin users

                               2003      2004      2005     2006     2007     2008     2009     2010     2011     2012     2013     2014     2015
  ---------------------------- --------- --------- -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- --------
  Number of new statin users   8205      8835      11 181   12 564   12 774   13 333   15 139   14 713   14 374   14 639   14 117   15 731   15 514
  Monotherapy (%)              **100**   **100**   **99**   **98**   **97**   **98**   **97**   **97**   **95**   **94**   **95**   **96**   **95**
   Atorvastatin                18        19        20       18       18       46       61       61       62       63       66       51       49
   Fluvastatin                 4         2         2        4        4        2        1        1        1        1        1        1        0
   Lovastatin                  30        18        12       6        4        2        1        1        1        0        0        0        0
   Pitavastatin                0         0         1        7        9        7        4        4        4        4        6        5        5
   Pravastatin                 11        8         6        5        4        4        3        3        3        2        2        2        1
   Rosuvastatin                0         2         7        9        8        7        7        9        8        8        8        33       36
   Simvastatin                 37        50        52       49       50       31       20       18       16       14       9        5        3
  Combination                  **0**     **0**     **1**    **2**    **3**    **2**    **3**    **3**    **5**    **6**    **5**    **4**    **5**
  Intensity (%)                                                                                                                              
   Low                         43        25        17       11       9        6        5        5        5        5        5        3        3
   Moderate                    57        75        83       88       90       94       94       94       93       93       93       92       92
   High                        0         0         0        0        1        1        1        2        2        2        2        4        5
  Institution (%)                                                                                                                            
   Primary                     63        61        59       59       58       58       56       56       56       57       56       58       58
   Secondary                   20        23        25       26       26       25       27       28       28       28       29       29       29
   Tertiary                    14        13        13       14       14       13       14       13       14       13       12       11       11
   Others                      3         2         2        2        3        3        4        3        3        2        2        2        2

The market for monotherapy statins is dynamic. In 2003, simvastatin (37%) was the most prescribed statin, followed by lovastatin (30%) and atorvastatin (18%). The market share of simvastatin had been the highest in the market from 2003 (37%) to 2007 (50%). During this period, the market share of atorvastatin was steady (18%--20%), while the market share of lovastatin decreased from 30% in 2003 to 4% in 2007. Similarly, the market share of simvastatin decreased after 2008, while the market share of atorvastatin increased and maintained the highest from 46% in 2008 to 66% in 2013. Lastly, the market share of rosuvastatin increased from 8% in 2013 to 36% in 2015, while that of atorvastatin decreased from 66% to 49% during the same period. In 2015, statins for new users were an oligopoly market: atorvastatin (49%) was the most prescribed statin, followed by rosuvastatin (36%).

In 2003, the prescription rates of low-intensity and moderate-intensity statins were 43% and 57%, respectively. However, the prescription rate of moderate-intensity statins consistently increased to 92% in 2015, while the prescription rate of low-intensity statins decreased to 3% in 2015. In addition, the use of high-intensity statins steadily increased during the study period. We also examined healthcare institutions that prescribed statins. In 2003, 63% of new statin users were prescribed at primary healthcare institutions followed by secondary (20%) and tertiary care institutions (14%). During the study period, the portion of new users prescribed at primary and tertiary healthcare institutions decreased, while the portion of new users prescribed at secondary healthcare institutions increased. In 2015, 58% of new statin users were prescribed at primary healthcare institutions followed by secondary (29%) and tertiary healthcare institutions (11%).

[Figure 1](#F1){ref-type="fig"} shows statin prescription by healthcare institutions and the intensity of prescribed statins. The first graph in [figure 1](#F1){ref-type="fig"} presents overall patterns of the prescription rates of low-intensity, moderate-intensity and high-intensity statins in all institution types. The remaining graphs indicate patterns of prescription rates in primary, secondary and tertiary healthcare institutions. We found that prescription rates of moderate-intensity statins were high in primary healthcare institutions, while those of high-intensity statins were high in tertiary care institutions. It is interesting to note that prescription rates of moderate-intensity statins in primary, secondary and tertiary healthcare institutions in 2003 was 48%, 69%, and 78%, respectively. However, prescription rates of moderate-intensity statins reversed in primary, secondary and tertiary healthcare institutions in 2015: 95%, 90% and 84%, respectively.

![Statin prescriptions by institution and intensity (A) all; (B) primary; (C) secondary; and (D) tertiary healthcare institutions.](bmjopen-2018-026603f01){#F1}

[Figure 2](#F2){ref-type="fig"} presents prescription rates of selected statins, including atorvastatin, rosuvastatin and simvastatin during the study period. The first graph in [figure 2](#F2){ref-type="fig"} shows market shares of selected statins among new statin users. Two points are noteworthy in the perspective of market dynamics. The first market dynamic occurred during 2007--2009. Specifically, atorvastatin penetrated the market of simvastatin in this period. Similarly, the second market dynamic occurred during 2013--2015. Rosuvastatin penetrated market of atorvastatin in this period. The remaining graphs present new statin users of selected statins by primary, secondary and tertiary healthcare institutions. In this figure, we conclude that the majority of market switching of statins among new statin users occurred immediately at primary healthcare institutions.

![Prescribing rates of selected statins among new statin users.](bmjopen-2018-026603f02){#F2}

[Table 3](#T3){ref-type="table"} indicates the associations between certain disease histories and the prescription of moderate-intensity or high-intensity statins. Interestingly, no substantial differences in the prescription of statins were observed through the study period in groups with histories of diseases of arteries, arterioles and capillaries. Furthermore, patients with history of diabetes, cerebrovascular diseases and ischaemic heart disease were less likely to be prescribed moderate-intensity or high-intensity statins in several selected years. For instance, ORs were calculated at 0.78 and ranged from 0.67 to 0.91 with 95% CI in 2012 for patients with diabetes.

###### 

Associations between disease history and prescription of moderated-intensity or high-intensity statins

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            2005         2006         2007         2008         2009         2010         2011         2012         2013         2014         2015
  ------------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------
  History of hypertension   1.04         1.16         1.04         0.92         1.01         0.98         1.09         1.04         1.02         1.05         1.20

  0.94--1.15                1.03--1.29   0.92--1.18   0.80--1.07   0.87--1.18   0.84--1.14   0.94--1.26   0.90--1.20   0.87--1.19   0.88--1.24   1.00--1.44   

  History of diabetes       1.12         1.15         0.99         0.94         0.75         0.82         0.78         0.78         0.92         0.83         0.92

  1.01--1.24                1.03--1.29   0.88--1.12   0.81--1.09   0.64--0.87   0.70--0.96   0.68--0.91   0.67--0.91   0.78--1.08   0.69--0.99   0.76--1.11   

  History of DoA            1.00         0.99         1.01         1.01         1.02         1.08         0.98         1.08         1.10         1.02         1.03

  0.87--1.15                0.86--1.14   0.87--1.18   0.85--1.20   0.85--1.21   0.91--1.30   0.83--1.17   0.91--1.31   0.91--1.34   0.82--1.25   0.82--1.30   

  History of CeVD           1.18         1.20         0.84         0.83         0.69         0.88         0.70         0.85         0.80         0.72         0.77

  1.00--1.38                1.01--1.42   0.71--0.99   0.69--1.01   0.57--0.83   0.71--1.08   0.58--0.84   0.70--1.04   0.65--0.98   0.58--0.90   0.60--0.98   

  History of\               1.41         1.26         1.04         1.02         0.76         0.75         0.94         0.88         1.01         1.06         0.92
  IHD                                                                                                                                                         

  1.24--1.60                1.09--1.44   0.90--1.21   0.85--1.22   0.64--0.91   0.63--0.90   0.78--1.13   0.73--1.06   0.82--1.23   0.85--1.33   0.72--1.18   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

CeVD, cerebrovascular diseases; DoA, diseases of arteries, arterioles and capillaries; IHD, ischaemic heart disease.

Interrupted time series analysis {#s3c}
--------------------------------

[Table 4](#T4){ref-type="table"} presents results of segmented regression analysis using the interrupted time series method: β~0~ is the preperiod intercept; β~1~ is the preperiod slope (baseline time trend); β~2~ is the immediate effect of the event on the intercept; and β~3~ is the slope change after the event. In the case of atorvastatin, the immediate effect of marketing generics was 3236 new users (p\<0.001), and the growth rate was increased by 2687 new users per year (p\<0.005) compared with previous trends. Similar trends were found in the case of rosuvastatin.

###### 

Results of segmented regression analysis of interrupted time series method

                              Total    Primary care   Secondary care   Tertiary care                                                                 
  --------------------------- -------- -------------- ---------------- --------------- ------ ---------- -------- ------- ---------- ------- ------- ----------
  Atorvastatin (2003--2009)                                                                                                                          
   β~0~: intercept            2611.9   168.5          \<0.001          850.3           46.4   \<0.001    1109.8   102.7   \<0.005    651.8   38.7    \<0.001
   β~1~: time                 221.5    50.8           \<0.05           75.1            14.0   \<0.05     108.2    32.5    \<0.05     38.2    11.7    \<0.05
   β~2~: generic              3236.1   232.8          \<0.001          2846.7          64.1   \<0.0001   373.2    148.8   0.087      16.2    53.5    0.78
   β~3~: time:generic         2687.5   232.8          \<0.05           1597.9          64.1   \<0.0001   736.8    148.8   \<0.05     352.8   53.5    \<0.01
  Rosuvastatin (2004--2015)                                                                                                                          
   β~0~: intercept            1376.5   141.9          \<0.001          295.7           29.1   \<0.001    655.9    59.0    \<0.001    424.9   61.8    \<0.0001
   β~1~: time                 76.1     22.9           \<0.05           13.5            4.7    \<0.05     42.8     9.5     \<0.005    19.8    10.0    0.08
   β~2~: generic              3687.5   251.6          \<0.0001         3163.3          51.6   \<0.0001   517.1    104.5   \<0.0051   7.1     109.6   0.95
   β~3~: time:generic         2453.9   294.7          \<0.0001         177.5           60.4   \<0.05     2243.2   122.4   \<0.0001   33.2    128.4   0.80

Notes: β0 is the preperiod intercept; β1 is the preperiod slope (baseline time trend); β2 is the immediate effect of the event on the intercept; β3 is the slope change after the event.

Discussions {#s4}
===========

This 13-year longitudinal study of a sample cohort provided by the NHIS found that incidence of new statin user increase from 838.1/100 000 persons in 2003 to 1626.9/100 000 persons in 2015. Most new users were initiated on a monotherapy that was prescribed at primary healthcare institutions. In addition, the use of moderate-intensity statins increased, notably at primary healthcare institutions. Specifically, the prescription rate of moderate-intensity statins at primary healthcare institutions was low (48%) in 2003. However, the figure was doubled in 2015 (95%).

The characteristics of new statin users and healthcare institutions that prescribed statins were similar to other studies that investigated prescription patterns of all statin users in Korea.[@R2] It is noteworthy to compare the results of statin prescription for new users with other countries[@R32]: statin market for new users is quite dynamic in Korea.

First, the most commonly used statin changed several times during the study period in Korea, while atorvastatin has been the most prescribed statin during 2002--2011 in Taiwan.[@R32] For instance, simvastatin had the highest prescription rate until 2007, while atorvastatin had the highest prescription rate after 2008. It should be noted that generics of atorvastatin were available with discounted prices compared with the originals of the previous year (approximately 68%) in 2008, and the price of the originals was discounted approximately 20% compared with the previous year. We could find similar results in the case of rosuvastatin. Generics of rosuvastatin were available in 2010, and the prices of generics were \$0.41 (exchange rate is 1100 won/dollar), \$0.61 and \$0.81 for a single tablet of 5 mg, 10 mg and 20 mg, respectively, which account for approximately 68% of the original counterparts. In such a case of the introduction of generics, the prices of originals would be decreased to 80% compared with the previous year. However, price reduction was deferred until 2014 in this case for the reason of valid patent that original rosuvastatin has until 2014. In the end, the price of original rosuvastatin decreased to approximately 80% compared with that of the previous year in 2014. It is interesting to note the prescription rates of rosuvastatin: the market share of rosuvastatin in 2009 was 7% and slightly increased 9% in 2010 when generics with discounted prices (approximately 32%) were marketed and later increased 33% in 2014 when prices of the original were discounted (approximately 20%). It means that the sole introduction of generics is not quite effective in expanding the market in Korea. However, discounted price of the original after the introduction of generics was related with the market expansion.

Interestingly, patterns of prescription found in this study is quite different from other studies in different regions. For instance, the incidence of new treatments decreased for atorvastatin and increased for simvastatin in Italy, Denmark and Spain[@R42]. Specifically, the market share of statin for new users in Southern Italian primary care was in the order of simvastatin (34%), atorvastatin (26.6%) and rosuvastatin (15.4%).[@R42] Furthermore, the vast majority of new users were started treatments with simvastatin in Northern Denmark from 2004 to 2010.[@R46] However, in Korea, simvastatin has been losing market share since 2008, and the current market share of simvastatin is marginal (3%) in 2015.

Second, the portion of moderate-intensity statins was high in Korea, which is not common in other countries. For instance, the portion of low-intensity, moderate-intensity and high-intensity statins among new statin users in Korea was 5%, 93% and 2% in 2011. However, the portion of low-intensity, moderate-intensity and high-intensity statins in Taiwan was 27%, 71% and 2% in the same year. Lastly, the portion of low-intensity, moderate-intensity and high-intensity statins in Spain was 4%, 72% and 24% from 2006 to 2010. Given these findings, we could conclude that Korean general practitioners or specialists frequently prescribes moderate-intensity statins. In line with this result, we found no substantial differences in the prescription of moderate-intensity or high-intensity statins in groups with histories of hypertension, diabetes, diseases of arteries, arterioles and capillaries, cerebrovascular diseases and ischaemic heart disease in Korea.

Korean guidelines for the management of dyslipidaemia states that the first goal is LDL-C.[@R47] Statin is the first-choice drug for the treatment of hypercholesterolaemia (class of recommendation I, level of evidence A) because it has a relatively low-risk profile and proven effects of decreasing CVD by lowering LDL-C. '*Statins should be prescribed*' and the dose adjusted to reach the LDL-C target level for high-risk and very high-risk groups (I, A), whereas '*statin use should be considered*' if LDL-C is not reduced to the first target even after lifestyle modification for weeks or months (IIa, B). The guidelines also provide dosage and administration of statins: lovastatin 20--80 mg/day, pravastatin 10--40 mg/day, simvastatin 20--40 mg/day, fluvastatin 20--80 mg/day, atorvastatin 10--80 mg/day, rosuvastatin 5--20 mg/day and pitavastatin 1--4 mg/day. Interestingly, atorvastatin and rosuvastatin, the top 2 best-selling statins in Korea, was recommended as moderate-intensity and high-intensity dosage.

In addition, we found that the pricing and marketing strategies of manufacturers might encourage physicians to prescribe moderate-intensity and high-intensity statins. For instance, the manufacturer discounted the price of simvastatin 40 mg (approximately 34%) in 2003, and the price was the same as simvastatin 20 mg. Likewise, the other manufacturer that produce atorvastatin used the same strategy: the manufacturer discounted the price of atorvastatin 40 mg (35%) in 2003, and the price was the same as atorvastatin 20 mg; and the manufacturer discounted the price of atorvastatin 20 mg (30%) in 2007, which was the same price as atorvastatin 10 mg. In addition, the manufacturer marketed atorvastatin 80 mg in the market to pre-empt the high-strength statins market in 2008.

Third, we found market expansion when price of original statins were discounted. It is interesting to analyse market expansion by healthcare institutions. In cases of atorvastatin and rosuvastatin, the immediate effect of the event was large in primary healthcare institutions. For instance, the immediate effect of marketing generics of rosuvastatin was 3163 users (p\<0.0000) and 517 users (p\<0.005) in primary and secondary healthcare institutions, respectively. However, the immediate effect of the event in tertiary care institutions was marginal and insignificant: 16.2 (p=0.78) for atorvastatin and 7.1 (p=0.95) for rosuvastatin. These results demonstrate that the discounted price of originals after the introduction of generics immediately expands markets, particularly in primary healthcare institutions. However, the growth rates, sorted by healthcare institutions, after the event vary according to drugs. For instance, the growth rate of atorvastatin was in the order of primary, secondary and tertiary healthcare institutions: 1597 (p\<0.0001), 736 (p\<0.05) and 352 (p\<0.001), respectively, while that of simvastatin was in the order of secondary, primary and tertiary healthcare institutions: 2243 (p\<0.0001), 178 (p\<0.05) and 33 (p=0.80), respectively.

This study notably analysed the utilisation of statins for new statin users and assessed the market dynamics of statins over the last 13 years with a real-world dataset provided by the NHIS. However, this study has several limitations. First, this study used claims data that do not contain information on biochemical test data of patients, such as LDL-C level. It means that we could not assess prescription patterns by disease severity. In addition, the claims data do not contain information on whether the prescribed drugs were originals or generics. Therefore, further research is needed to assess the impact of generics on the market, including the contribution to market expansion by originals and generics, respectively. Second, this study used sample data and assumed that the data are to be representative, yet attention should be paid when generalise our results. Third, this study only used the first prescription that included any statins. Therefore, switches among statins were not included in the study. However, it would be reasonable to assume that switches among statins would be low in the Korean market.[@R2] Lastly, we noted the dosing for statins increased in Korea and partially explained this trends with the Korean guidelines for the management of dyslipidaemia and the pricing and marketing strategies of manufacturers. However, further qualitative methods are needed to understand these interesting observations.

Conclusions {#s5}
===========

Similar to other countries, the incidence of new statin users has been increased in Korea. However, the statin market in Korea is quite dynamic compared with other countries. It is noteworthy that the portion of new statin users that were prescribed moderate-intensity statins has increased during the study period. In addition, no substantial differences in the prescriptions of statins were observed in groups with selected disease histories. Interestingly, discounted price of originals after the introduction of generics immediately expand markets or substitute the market particularly in primary healthcare institutions in Korea.
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